Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rimiterol
- Development stage
- Discontinued
- Lead developer
- Riker Laboratories
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Rimiterol is a third-generation, short-acting β2-adrenergic receptor agonist and direct-acting sympathomimetic bronchodilator. It acts primarily by selectively binding to β2-adrenoreceptors on bronchial smooth muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP), which leads to relaxation of bronchial smooth muscle and bronchodilation. Rimiterol is used in the management of bronchial asthma and has a rapid onset of action due to its high affinity for β2-adrenoreceptors. Systemic administration can also produce cardiovascular effects such as increased heart rate and muscle tremor. The drug was initially developed by Riker Laboratories.
- Other names
- rimiterol hydrobromide
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on Rimiterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rimiterol.